Log In
Print
BCIQ
Print
Print this Print this
 

Victrelis, boceprevir (MK-3034) (formerly SCH 503034)

  Manage Alerts
Collapse Summary General Information
Company Merck & Co. Inc.
DescriptionSmall molecule HCV NS3/4A protease inhibitor
Molecular Target HCV NS3/4A protease complex
Mechanism of ActionViral protease inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationHepatitis C virus (HCV)
Indication DetailsTreat chronic HCV genotype 1 infection; Treat chronic HCV genotype 1 infection in combination with standard of care in adults with compensated liver disease who are treatment naïve or have failed treatment; Treat chronic HCV genotype 1 infection in patients who failed prior therapy; Treat chronic HCV genotype 1 infection in patients who failed prior therapy and treatment-naïve patients; Treat chronic HCV genotype 1 infection in treatment-naïve patients; Treat patients co-infected with HCV and HIV
Regulatory Designation U.S. - Fast Track (Treat chronic HCV genotype 1 infection);
EU - Accelerated Assessment (Treat chronic HCV genotype 1 infection)
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today